A Systematic Review of Economic Evaluation Studies of Drug-Based Non-Malignant Chronic Pain Treatment

Author(s): Insa Backhaus, Alice Mannocci, Giuseppe La Torre*

Journal Name: Current Pharmaceutical Biotechnology

Volume 20 , Issue 11 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background and Objective: Chronic pain is a highly prevalent problem, involving high costs and seriously affecting a patient's quality of life. This review aimed to systematically review economic evaluations of pharmacological-based treatments for non-malignant chronic pain and to compare different treatment approaches with regard to their economic profile.

Methods: PubMed and Scopus were systematically searched in April 2016. Studies were included if quality-adjusted life years and incremental cost-effectiveness ratios were reported. Quality assessment was carried out by using La Torre’s weighted scale on the Drummond checklist. Costs were converted into US$2014.

Results: Fourteen economic evaluations met the inclusion criteria. Three treatment categories identified were: opioids, anticonvulsants, and anti-depressants. Compared to anticonvulsants and antidepressant, opioids had lower ICER. Transdermal buprenorphine showed an ICER of about US$11,000.00 while pregabalin showed an ICER of US$19,200. Studies included showed a diversity of methodological approaches, such as different modeling approaches and different perspectives (NHS and private payer).

Conclusion: There are limitations to the success of making appropriate recommendations about which treatment is most cost-effective due to considerable variability between treatments, pain syndromes, and drug dosages. Opioids may have lower ICER, but the societal implications of the opioid epidemic and overdose deaths should be taken into account when coming to general conclusions about their cost-effectiveness. To ensure correct resource allocation as well as the best benefit for patients, uniform and standardized approaches of cost and outcome measurement in economic evaluations of chronic are needed.

Keywords: Chronic Pain, cost-effectiveness, economic evaluation, opioids, non-opioids.

[1]
van Tulder, M.W.; Koes, B.W.; Bouter, L.M. A cost-of-illness study of back pain in The Netherlands. Pain, 1995, 62(2), 233-240.
[http://dx.doi.org/10.1016/0304-3959(94)00272-G] [PMID: 8545149]
[2]
Breivik, H.; Eisenberg, E.; O’Brien, T. The individual and societal burden of chronic pain in Europe: The case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health, 2013, 13, 1229.
[http://dx.doi.org/10.1186/1471-2458-13-1229] [PMID: 24365383]
[3]
Dahlhamer, J.; Lucas, J.; Zelaya, C.; Nahin, R.; Mackey, S.; DeBar, L.; Kerns, R.; Von Korff, M.; Porter, L.; Helmick, C. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb. Mortal. Wkly. Rep., 2018, 67(36), 1001-1006.
[http://dx.doi.org/10.15585/mmwr.mm6736a2] [PMID: 30212442]
[4]
Reid, K.J.; Harker, J.; Bala, M.M.; Truyers, C.; Kellen, E.; Bekkering, G.E.; Kleijnen, J. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr. Med. Res. Opin., 2011, 27(2), 449-462.
[http://dx.doi.org/10.1185/03007995.2010.545813] [PMID: 21194394]
[5]
Dahan, A.; van Velzen, M.; Niesters, M. Comorbidities and the complexities of chronic pain. Anesthesiology, 2014, 121(4), 675-677.
[http://dx.doi.org/10.1097/ALN.0000000000000402] [PMID: 25099749]
[6]
Long, D.M. Bonica’s Management of Pain; Third Edition. J Pain Symptom Manage, 2001, 21, 527-8.
[7]
Turk, D.C. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin. J. Pain, 2002, 18(6), 355-365.
[http://dx.doi.org/10.1097/00002508-200211000-00003] [PMID: 12441829]
[8]
Dalton, K.; Byrne, S. Role of the pharmacist in reducing healthcare costs: current insights. Integr. Pharm. Res. Pract., 2017, 6, 37-46.
[http://dx.doi.org/10.2147/IPRP.S108047] [PMID: 29354549]
[9]
Breivik, H.; Collett, B.; Ventafridda, V.; Cohen, R.; Gallacher, D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur. J. Pain, 2006, 10(4), 287-333.
[http://dx.doi.org/10.1016/j.ejpain.2005.06.009] [PMID: 16095934]
[10]
Gaskin, D.J.; Richard, P. The economic costs of pain in the United States. J. Pain, 2012, 13(8), 715-724.
[http://dx.doi.org/10.1016/j.jpain.2012.03.009] [PMID: 22607834]
[11]
Rastogi, R.; Meek, B.D. Management of chronic pain in elderly, frail patients: Finding a suitable, personalized method of control. Clin. Interv. Aging, 2013, 8, 37-46.
[http://dx.doi.org/10.2147/CIA.S30165] [PMID: 23355774]
[12]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J. Clin. Epidemiol., 2009, 62(10), e1-e34.
[http://dx.doi.org/10.1016/j.jclinepi.2009.06.006] [PMID: 19631507]
[13]
Opioids for persistent pain: Summary of guidance on good practice from the British Pain Society. Br. J. Pain, 2012, 6(1), 9-10.
[http://dx.doi.org/10.1177/2049463712436536] [PMID: 26516460]
[14]
Hauber, A.B.; Fleischmann, J.; Lothgren, M.; Wilson, M.; Lam, A.; Dubois, D.; Sabatowski, R. Economic evaluation of OROS hydromorphone for chronic pain: A Pan-European perspective. J. Opioid. Manag., 2011, 7(4), 287-296.
[http://dx.doi.org/10.5055/jom.2011.0070] [PMID: 21957828]
[15]
Vargas-Schaffer, G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician Med Fam Can, 2010, 56, 514-517.
[16]
Dunlop, W.; Uhl, R.; Khan, I.; Taylor, A.; Barton, G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J. Med. Econ., 2012, 15(3), 564-575.
[http://dx.doi.org/10.3111/13696998.2012.665279] [PMID: 22313329]
[17]
Frei, A.; Andersen, S.; Hole, P.; Jensen, N-H. A one-year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J. Pain Palliat. Care Pharmacother., 2003, 17(2), 5-26.
[http://dx.doi.org/10.1080/J354v17n02_02] [PMID: 14649386]
[18]
Goeree, R.; Goeree, J. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. J. Med. Econ., 2016, 19(3), 277-291.
[http://dx.doi.org/10.3111/13696998.2015.1116992] [PMID: 26535790]
[19]
Greiner, W.; Lehmann, K.; Earnshaw, S.; Bug, C.; Sabatowski, R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur. J. Health Econ., 2006, 7(4), 290-296.
[http://dx.doi.org/10.1007/s10198-006-0376-8] [PMID: 16983521]
[20]
Ikenberg, R.; Hertel, N.; Moore, R.A.; Obradovic, M.; Baxter, G.; Conway, P.; Liedgens, H. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J. Med. Econ., 2012, 15(4), 724-736.
[http://dx.doi.org/10.3111/13696998.2012.670174] [PMID: 22364286]
[21]
Neighbors, D.M.; Bell, T.J.; Wilson, J.; Dodd, S.L. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J. Pain Symptom Manage., 2001, 21(2), 129-143.
[http://dx.doi.org/10.1016/S0885-3924(00)00247-5] [PMID: 11226764]
[22]
Obradovic, M.; Lal, A.; Liedgens, H. Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain. Health Qual. Life Outcomes, 2013, 11, 110.
[http://dx.doi.org/10.1186/1477-7525-11-110] [PMID: 23815777]
[23]
Radbruch, L.; Lehmann, K.; Gockel, H-H.; Neighbors, D.; Nuyts, G. Costs of opioid therapy for chronic nonmalignant pain in Germany: An economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur. J. Health Econ., 2002, 3(2), 111-119.
[http://dx.doi.org/10.1007/s10198-002-0097-6] [PMID: 24577592]
[24]
Ward, A.; Bozkaya, D.; Fleischmann, J.; Dubois, D.; Sabatowski, R.; Caro, J.J. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: Comparison of extended-release oxycodone and OROS hydromorphone. Curr. Med. Res. Opin., 2007, 23(10), 2333-2345.
[http://dx.doi.org/10.1185/030079907X219643] [PMID: 17697453]
[25]
Choy, E.; Richards, S.; Bowrin, K.; Watson, P.; Lloyd, A.; Sadosky, A.; Zlateva, G. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr. Med. Res. Opin., 2010, 26(4), 965-975.
[http://dx.doi.org/10.1185/03007991003600271] [PMID: 20178405]
[26]
Igarashi, A.; Akazawa, M.; Murata, T.; Taguchi, T.; Sadosky, A.; Ebata, N.; Willke, R.; Fujii, K.; Doherty, J.; Kobayashi, M. Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan. Clinicoecon. Outcomes Res., 2015, 7, 505-520.
[http://dx.doi.org/10.2147/CEOR.S89833] [PMID: 26504403]
[27]
Chan, H.N.; Fam, J.; Ng, B.Y. Use of antidepressants in the treatment of chronic pain. Ann. Acad. Med. Singapore, 2009, 38(11), 974-979.
[PMID: 19956820]
[28]
Wielage, R.C.; Bansal, M.; Andrews, J.S.; Wohlreich, M.M.; Klein, R.W.; Happich, M. The cost-effectiveness of duloxetine in chronic low back pain: A US private payer perspective. Value Health, 2013, 16(2), 334-344.
[http://dx.doi.org/10.1016/j.jval.2012.12.006] [PMID: 23538186]
[29]
Dewilde, S.; Verdian, L.; Maclaine, G.D.H. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr. Med. Res. Opin., 2009, 25(8), 2007-2019.
[http://dx.doi.org/10.1185/03007990903090849] [PMID: 19563256]
[30]
Hass, B.; Lungershausen, J.; Hertel, N.; Poulsen, N.B.; Kotowa, W.; Liedgens, H. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: A model approach. Eur. J. Health Econ., 2009, 10(3), 309-321.
[http://dx.doi.org/10.1007/s10198-008-0134-1] [PMID: 19101743]
[31]
Kumar, K.; Rizvi, S. Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain. Pain Med., 2013, 14(11), 1631-1649.
[http://dx.doi.org/10.1111/pme.12146] [PMID: 23710759]
[32]
Norrlid, H.; Dahm, P.; Tennvall, G.R. Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights. Scand. J. Pain, 2015, 6(1), 24-30.
[http://dx.doi.org/10.1016/j.sjpain.2014.07.002] [PMID: 29911578]
[33]
Neil, N.; Merchant, S.; Provenzano, D.; Ogden, K.; Mody, S.H. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States. J. Med. Econ., 2013, 16(2), 307-317.
[http://dx.doi.org/10.3111/13696998.2012.756401] [PMID: 23216013]
[34]
Lloyd, A.; Boomershine, C.S.; Choy, E.H.; Chandran, A.; Zlateva, G. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J. Med. Econ., 2012, 15(3), 481-492.
[http://dx.doi.org/10.3111/13696998.2012.660254] [PMID: 22339078]
[35]
Polinder, S.; Segui-Gomez, M.; Toet, H.; Belt, E.; Sethi, D.; Racioppi, F.; van Beeck, E.F. Systematic review and quality assessment of economic evaluation studies of injury prevention. Accid. Anal. Prev., 2012, 45, 211-221.
[http://dx.doi.org/10.1016/j.aap.2011.07.004] [PMID: 22269503]
[36]
Stewart, W.F.; Ricci, J.A.; Chee, E.; Morganstein, D.; Lipton, R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA, 2003, 290(18), 2443-2454.
[http://dx.doi.org/10.1001/jama.290.18.2443] [PMID: 14612481]
[37]
Obradovic, M.; Ikenberg, R.; Hertel, N.; Antoñanzas, F.; Gálvez, R.; Liedgens, H. Cost-effectiveness of tapentadol in severe chronic pain in Spain: A cost analysis of data from RCTs. Clin. Ther., 2012, 34(4), 926-943.
[http://dx.doi.org/10.1016/j.clinthera.2012.02.011] [PMID: 22417717]
[38]
Chou, R.; Turner, J.A.; Devine, E.B.; Hansen, R.N.; Sullivan, S.D.; Blazina, I.; Dana, T.; Bougatsos, C.; Deyo, R.A. The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann. Intern. Med., 2015, 162(4), 276-286.
[http://dx.doi.org/10.7326/M14-2559] [PMID: 25581257]
[39]
Carleton, R.N. Into the unknown: A review and synthesis of contemporary models involving uncertainty. J. Anxiety Disord., 2016, 39, 30-43.
[http://dx.doi.org/10.1016/j.janxdis.2016.02.007] [PMID: 26945765]
[40]
Anderson, R. Systematic reviews of economic evaluations: Utility or futility? Health Econ., 2010, 19(3), 350-364.
[http://dx.doi.org/10.1002/hec.1486] [PMID: 19378354]
[41]
Novick, L.F.; Morrow, C.B.; Mays, G.P. Public Health Administration: Principles for Population-Based Management, 2nd ed; Jones & Bartlett Publishers, 2008.
[42]
Oster, G. Re: Economic evaluation of fentanyl. J. Pain Symptom Manage., 2001, 22(1), 540-543.
[http://dx.doi.org/10.1016/S0885-3924(01)00307-4] [PMID: 11523517]
[43]
Haas, M.; De Abreu Lourenco, R. Pharmacological management of chronic lower back pain: A review of cost effectiveness. Pharmacoeconomics, 2015, 33(6), 561-569.
[http://dx.doi.org/10.1007/s40273-015-0258-y] [PMID: 25604096]
[44]
Sullivan, W.; Hirst, M.; Beard, S.; Gladwell, D.; Fagnani, F.; López Bastida, J.; Phillips, C.; Dunlop, W.C. Economic evaluation in chronic pain: A systematic review and de novo flexible economic model. Eur. J. Health Econ., 2016, 17(6), 755-770.
[http://dx.doi.org/10.1007/s10198-015-0720-y] [PMID: 26377997]
[45]
National Center for Health Statistic. Wide-ranging online data for epidemiologic research (WONDER). 2017 http://wonder.cdc.gov
[46]
Gomes, T.; Mamdani, M.M.; Dhalla, I.A.; Paterson, J.M.; Juurlink, D.N. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch. Intern. Med., 2011, 171(7), 686-691.
[http://dx.doi.org/10.1001/archinternmed.2011.117] [PMID: 21482846]
[47]
Dillie, K.S.; Fleming, M.F.; Mundt, M.P.; French, M.T. Quality of life associated with daily opioid therapy in a primary care chronic pain sample. J. Am. Board Fam. Med., 2008, 21(2), 108-117.
[http://dx.doi.org/10.3122/jabfm.2008.02.070144] [PMID: 18343858]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 11
Year: 2019
Published on: 30 September, 2019
Page: [910 - 919]
Pages: 10
DOI: 10.2174/1389201020666190717095443
Price: $65

Article Metrics

PDF: 39
HTML: 3
EPUB: 1
PRC: 1